NEB UK supplies a broad range of reagents and kits for basic and applied research at the DNA, RNA and protein levels. These products are also for use in drug development and screening, as well as for use in platform technologies and as raw materials in kit manufacture. We supply standard catalogue products as well as custom and bulk formulations. We would like to partner with you from R&D downstream to market. Call us to discuss your ‘biological component’ needs.
New Path Molecular specialises in the chemical synthesis of complex functional molecules using the cutting edge techniques, methods and instrumentation developed in the laboratories of Prof Steve Ley at the University of Cambridge. Our processes and molecules are being used to validate biological processes and produce products globally.
In order to develop drugs to treat or prevent human disease a significant amount of complex scientific research needs to be done. Nexus BioQuest is a pre-clinical contract research organisation that collaborates with Biotechnology and Pharmaceutical companies in order to help accelerate their pre-clinical immunology research programmes. At our core we have: • Expertise- Deep immunology experience and knowledge in order to solve complex research problems. • Tempo- Agile and quickly expandable capability focused on reducing bureaucracy and burden so that collaborative science can thrive. • Collaboration- Be open and mutually trusting to maximise the impact of research and step away from a transactional approach. Our science will provide a comprehensive suite of solutions which will model the immune response depending on the research question being asked. These will form a pre-clinical package of assays including: • Relevant target expression. • Mode of action. • Efficacy. • Biomarkers. • Predictive immuno-toxicity. This will allow us to support our partners at multiple steps within the preclinical drug development process. All of our work is built on our deep understanding of the immune response, allowing us to provide relevant, customisable, cutting-edge assays, to advance our partners' drug development programs.
No data available
Norwich Research Park is one of five BBSRC funded UK Research and Innovation Campuses. It is the only site with three BBSRC funded research Institutes in the UK. The site also has a fourth research institute, a University, a University Hospital and a community of over 30 businesses.
Norwich Research Park offers businesses access to a specialist skills pool, and opportunities to collaborate and win global business at a unique research campus environment, with a community that is working together, as a powerful cluster of activity, specializing in food biotech, agricultural biotech and industrial biotech, applied to the effects of climate change and improvements to human health, using nature to solve the world’s problems.
Website: http://www.norwichresearchpark.com/
Contact: enquiries@norwichresearchpark.com
Watch our Member Showcase Video https://bit.ly/34Uy63y
Norwich Research Park offers businesses access to a specialist skills pool, and opportunities to collaborate and win global business at a unique research campus environment, with a community that is working together, as a powerful cluster of activity, specializing in food biotech, agricultural biotech and industrial biotech, applied to the effects of climate change and improvements to human health, using nature to solve the world’s problems.
Website: http://www.norwichresearchpark.com/
Contact: enquiries@norwichresearchpark.com
Watch our Member Showcase Video https://bit.ly/34Uy63y
No data available
No data available
Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
No data available